These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30922248)

  • 1. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.
    Fan Y; Li S; Ding X; Yue J; Jiang J; Zhao H; Hao R; Qiu W; Liu K; Li Y; Wang S; Zheng L; Ye B; Meng K; Xu B
    BMC Cancer; 2019 Mar; 19(1):279. PubMed ID: 30922248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
    Qin SK; Li Q; Ming Xu J; Liang J; Cheng Y; Fan Y; Jiang J; Ye H; Tao H; Li L; Zheng L; Wei Z; Li S; Meng K; Ye B; Sun Y
    Cancer Sci; 2020 Nov; 111(11):4218-4231. PubMed ID: 32889778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.
    Tao H; Liu M; Wang Y; Luo S; Xu Y; Ye B; Zheng L; Meng K; Li L
    Front Immunol; 2021; 12():609295. PubMed ID: 33717093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the anticancer therapeutic potential of icaritin and its synthetic derivatives.
    Reyes-Hernández OD; Figueroa-González G; Quintas-Granados LI; Hernández-Parra H; Peña-Corona SI; Cortés H; Kipchakbayeva A; Mukazhanova Z; Habtemariam S; Leyva-Gómez G; Büsselberg D; Sharifi-Rad J
    Drug Dev Res; 2024 Apr; 85(2):e22175. PubMed ID: 38567708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
    Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma.
    Lu Y; Gao Y; Yang H; Hu Y; Li X
    Mil Med Res; 2022 Dec; 9(1):69. PubMed ID: 36503490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
    Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
    Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
    Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
    Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S
    Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.
    Yeo W; Chan SL; Mo FK; Chu CM; Hui JW; Tong JH; Chan AW; Koh J; Hui EP; Loong H; Lee K; Li L; Ma B; To KF; Yu SC
    BMC Cancer; 2015 May; 15():395. PubMed ID: 25962426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
    Kanai F; Yoshida H; Tateishi R; Sato S; Kawabe T; Obi S; Kondo Y; Taniguchi M; Tagawa K; Ikeda M; Morizane C; Okusaka T; Arioka H; Shiina S; Omata M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):315-24. PubMed ID: 20390419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    Estfan B; Byrne M; Kim R
    Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
    Simonelli M; Zucali P; Santoro A; Thomas MB; de Braud FG; Borghaei H; Berlin J; Denlinger CS; Noberasco C; Rimassa L; Kim TY; English PA; Abbattista A; Gallo Stampino C; Carpentieri M; Williams JA
    Ann Oncol; 2016 Sep; 27(9):1782-7. PubMed ID: 27329247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
    Shao YY; Chen BB; Ou DL; Lin ZZ; Hsu CH; Wang MJ; Cheng AL; Hsu C
    Aliment Pharmacol Ther; 2017 Oct; 46(8):722-730. PubMed ID: 28815645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.